Latest News

May 22, 2023

London Stock Exchange Delisting

May 19, 2023

Commencement of trading of new ordinary shares on The Nasdaq Capital Market

May 15, 2023

Change of Record Time and Last Day of Dealings

May 11, 2023

OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform

May 11, 2023

Change of Delisting Date to 22 May 2023

May 3, 2023

Result of General Meeting

May 3, 2023

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

May 2, 2023

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease   

April 25, 2023

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

April 5, 2023

NOTICE OF GENERAL MEETING AND PUBLICATION OF CIRCULAR

April 4, 2023

NOTICE OF INTENTION TO DELIST FROM THE LONDON STOCK EXCHANGE

March 30, 2023

OKYO Pharma Today Announces Director Acquires Shares

March 29, 2023

March 24, 2023

OKYO Pharma Announces PDMR Dealing

March 16, 2023

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. 

March 16, 2023

Closing of Global Private Placement

March 15, 2023

OKYO Pharma announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee has awarded options to directors and persons discharging managerial responsibility.

March 14, 2023

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

March 13, 2023

CEO of OKYO Pharma, Inc., Dr. Gary Jacob, Interviewed by Leading Publisher,
SmallCapsDaily

February 28, 2023

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

February 23, 2023

World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma

February 21, 2023

OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

February 14, 2023

Allotment of Shares and Total Voting Rights

December 30, 2022

Interim Results for the Six Months Ending 30 September 2022

December 22, 2022

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

December 21, 2022

OKYO to Participate at Biotech Showcase

December 6, 2022

OKYO publicly files a registration statement with the SEC

December 1, 2022

Change of Auditor

November 24, 2022

Grant of options –PDMR dealing

November 21, 2022

OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

November 10, 2022

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

October 20, 2022

OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference

September 8, 2022

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

September 7, 2022

Result of Annual General Meeting

August 30, 2022

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

August 19, 2022

Notice of Annual General Meeting

August 16, 2022

Final audited results for the year ended 31 March 2022

June 9, 2022

PDMR Dealing

May 20, 2022

PDMR Dealing

May 19, 2022

OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

May 18, 2022

PDMR Dealing

May 17, 2022

OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation

April 27, 2022

OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

March 7, 2022

OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States

February 23, 2022

OKYO Pharma announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain

February 21, 2022

Conversion of CLNs, cashless exercise of Warrants, and issue of equity

February 15, 2022

Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease

February 1, 2022

Grant of options – Director and PDMR dealings

January 27, 2022

PDMR Dealing

January 26, 2022

OKYO Pharma Limited: Interim results for the six months to 30 September 2021

December 14, 2021

Issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease

December 13, 2021

First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

December 6, 2021

OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis

December 1, 2021

DIRECTORATE CHANGE

September 27, 2021

Result of Annual General Meeting

September 9, 2021

Notice of Annual General Meeting

September 1, 2021

Grant of options – Director dealings

August 2, 2021

Final audited results for the year ended 31 March 2021

June 29, 2021

OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications

June 17, 2021

DIRECTORATE CHANGE

May 12, 2021

TR-1: Standard form for notification of major holdings

May 7, 2021

Admission of additional shares to listing on the Official List and to trading on the London Stock Exchange and director dealing

May 5, 2021

Prospectus Publication Announcement

April 28, 2021

OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

March 29, 2021

OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer

March 10, 2021

OKYO Pharma Limited CEO Gary Jacob tells Proactive’s Andrew Scott it’s time to take the company from development stage and into the clinic

March 3, 2021

ISSUE OF EQUITY – UPDATE

March 1, 2021

ISSUE OF EQUITY

February 23, 2021

OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation

January 19, 2021

OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS

January 7, 2021

DIRECTORATE CHANGES AND PDMR DEALING

November 30, 2020

Interim results for the six months to 30 September 2020

September 25, 2020

Upload of Articles of Association to National Storage Mechanism

September 25, 2020

RESULT OF THE ANNUAL GENERAL MEETING

September 9, 2020

Notice of Annual General Meeting

September 8, 2020

Issue of convertible loan notes to raise an additional £500,000

August 21, 2020

Grant of options – Director dealings

August 19, 2020

Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board

August 18, 2020

Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ

August 17, 2020

Final audited results for the year ended 31 March 2020

August 7, 2020

Dr James Khodabakhsh MD named Chairman of the SAB

August 6, 2020

Holding(s) in Company

August 3, 2020

Company Presentation

July 31, 2020

Upcoming Presentation

July 28, 2020

Issue of convertible loan notes to raise £3,500,000

June 10, 2020

DIRECTORATE CHANGE

June 5, 2020

TR-1: Standard form for notification of major holdings

June 3, 2020

Appointment of Broker

May 29, 2020

Issue of convertible loan notes to raise £440,000

May 28, 2020

Balance of Placing to raise £560,000 announced on 23 March 2020

May 27, 2020

TR-1: Standard form for notification of major holdings

April 27, 2020

TR-1: Standard form for notification of major holdings

March 30, 2020

TR-1: Standard form for notification of major holdings

March 23, 2020

Update on Placing to raise £560,000

March 19, 2020

Placing to raise £560,000

March 2, 2020

Result of Annual General Meeting

December 19, 2019

DIRECTORATE CHANGE

November 29, 2019

Interim results for the six months to 30 September 2019

August 28, 2019

OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease

August 19, 2019

OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors

July 1, 2019

Final audited results for the year ended 31 March 2019

May 30, 2019

TR-1 – Notification of Major Holdings

May 20, 2019

Result of General Meeting, Admission of Subscription Shares and Total Voting Rights

April 26, 2019

Subscription of 36,363,636 new Ordinary Shares at a price of 1.1 pence per share to raise gross proceeds of £400,000 Proposed Approval of Waiver of the obligations under Rule 9 of the Takeover Code and Notice of General Meeting

March 14, 2019

OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye.

March 7, 2019

Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment

January 23, 2019

OKYO Pharma Corporate Update

November 30, 2018

Interim results for the six months to 30 September 2018

November 1, 2018

Expected Admission Date for Consideration Shares

October 24, 2018

Allotment of ordinary shares and listing application

September 12, 2018

OKYO Pharma sees big opportunities for its dry eye and pain management technology

September 6, 2018

Result of AGM

August 22, 2018

Notification of Major Holdings